AI assistant
TherapeuticsMD, Inc. — Director's Dealing 2022
Dec 10, 2022
35134_dirs_2022-12-09_e7b37ed3-e3c3-48f8-a3fd-f848c87e7653.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2022-12-06
Reporting Person: Glickman Mark A (Co-Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-06 | Common Stock | M | 1734 | $0.00 | Acquired | 1734 | Direct |
| 2022-12-06 | Common Stock | S | 440 | $4.9215 | Disposed | 1294 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-06 | Restricted Stock Units | $0.00 | M | 1734 | Disposed | Common Stock (1734) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
F3: The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.